

**DESIGN, SYNTHESIS, *IN SILICO* AND *IN VITRO*
EVALUATIONS OF NEW INHIBITORS
TARGETING HUMAN HYPOXIA INDUCIBLE
FACTOR (HIF) PROLYL HYDROXYLASE
DOMAIN (PHD) ENZYMES**

SAYAF ABRAR MOHAMMAD

UNIVERSITI SAINS MALAYSIA

2025

**DESIGN, SYNTHESIS, *IN SILICO* AND *IN VITRO*
EVALUATIONS OF NEW INHIBITORS
TARGETING HUMAN HYPOXIA INDUCIBLE
FACTOR (HIF) PROLYL HYDROXYLASE
DOMAIN (PHD) ENZYMES**

by

SAYAF ABRAR MOHAMMAD

**Thesis submitted in fulfilment of the requirements
for the degree of
Doctor of Philosophy**

September 2025

ACKNOWLEDGEMENT

All praise is due to **Allah Almighty**, whose infinite blessings, guidance, and mercy have been my strength throughout this journey. Without His grace, none of this would have been possible.

I extend my deepest gratitude to my supervisor, Dr. Yeoh Kar Kheng, for his invaluable mentorship, patience, and unwavering support. His guidance has shaped my academic path at Universiti Sains Malaysia (USM). Special thanks to my co-supervisor, Dr. Oo Chuan Wei, for his insightful contributions and constant encouragement. I sincerely appreciate Prof. Dr. Christopher J. Schofield and his CJS research group at CRL, University of Oxford, where I conducted a significant part of this work. A heartfelt thank you to Dr. Anthony Tumber, Dr. James Holt-Martyn, Dr. Eidarus Salah, Mohammad Parsa Jabbary, Sam Atwal, and Thomas Corner for their expertise and assistance. I also extend my gratitude to Dr. Abbas Khan, Sunway University, Malaysia and Dr. Muhammad Suleman, University of Swat, Pakistan for their invaluable computational support.

My time at USM has been transformative, filled with learning, challenges, and friendships. I am deeply grateful to USM, FRGS, and GRA-ASSIST for their support. The friendships of Ikram Ullah and Habibur Rahaman Khan have made this journey truly special.

Above all, my deepest gratitude goes to my parents, Khaista Mohammad and my beloved mother, for their endless sacrifices, prayers, and unconditional love. To my siblings and Dr. Latipah Binti Latip, your support has been my strength. I dedicate this PhD to my family, especially my parents. May Allah bless you all, and may this journey contribute to knowledge and humanity. **Ameen.**

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS.....	iii
LIST OF TABLES	xi
LIST OF FIGURES	xiv
LIST OF ABBREVIATIONS	xxv
LIST OF APPENDICES	xxix
ABSTRAK	xxx
ABSTRACT	xxxii
CHAPTER 1 INTRODUCTION	1
1.1 Background	1
1.2 Hypoxia.....	2
1.3 Hypoxia inducible factors (HIFs)	3
1.4 The hypoxia signaling pathway	4
1.5 2-Oxoglutarate (2OG)	8
1.6 2OG dependent oxygenases (2OGXs)	10
1.7 PHD diversity and distribution	13
1.7.1 PHD Isoforms	14
1.7.2 Structural characteristics of PHDs.....	15
1.7.3 PHDs as oxygen sensors.....	17
1.8 Problem statement.....	18
1.9 Research objectives.....	20
1.10 Scope of study.....	21
CHAPTER 2 LITERATURE REVIEW	23

2.1	Historical overview of HIF research	24
2.2	HIF-regulated genes and their functions	27
2.3	PHD inhibitors: Therapeutic uses, current studies, and opportunities	28
2.4	Different classes of PHDs inhibitors.....	30
2.4.1	Divalent transition metal ions	31
2.4.2	Iron chelators	31
2.4.3	Carboxylic acid-based PHD inhibitors (CABPIs)	32
2.4.3(a)	Isoquinoline derivatives.....	35
2.4.3(b)	Pyridines derivatives	37
2.4.3(c)	Pyrimidinone and pyridone derivatives.....	38
2.4.3(d)	Triazolopyridine derivatives.....	41
2.4.3(e)	Benzimidazole derivatives.....	43
2.4.3(f)	Pyrimidine and related derivatives	44
2.4.4	Non-carboxylic acid based PHD inhibitors (NCABPIs)	46
2.4.4(a)	Quinazoline and pyridone derivatives	46
2.4.4(b)	Pyrimidine derivatives.....	47
2.4.4(c)	Spiroindolone and spirohydantoin derivatives	48
2.4.4(d)	Pyrazole and pyrazolon derivatives.....	50
2.4.4(e)	Triazole and thiazole derivatives.....	53
2.4.5	Non-conventional PHD inhibitors (NCPIs).....	54
2.5	CADD in drug discovery	56
2.5.1	Applications of CADD	57
2.5.2	Limitations of CADD	59
2.5.3	Future challenges in CADD.....	60
2.6	Amide bond and PHD inhibitors.....	61

2.6.1	Amide bonds	61
2.6.1(a)	Amide Bonds: Crucial for drug development and PHD inhibitors	62
2.6.1(b)	Challenges and advancements in amide synthesis	63
2.6.1(c)	Amides from cyclic anhydrides	64
CHAPTER 3 MATERIALS AND METHODS		65
3.1	Protein retrieval and preparation	66
3.2	Data set preparation for each study	67
3.3	Re-docking of the positive controls for docking validation	71
3.4	Virtual drugs screening	71
3.5	Visualization of ligand-protein interactions	72
3.6	Molecular, drug-likeness and pharmacokinetics evaluation.	73
3.7	Molecular dynamics simulations of ligand-protein complexes	73
3.8	Binding free energy with MM/GBSA method	74
3.9	AutoQSAR module for QSAR model development	75
3.10	Chemicals, reagents and solvents	76
3.11	Reaction monitoring	77
3.12	Isolation and purification by Column chromatography	78
3.13	Characterization of compounds	78
3.13.1	Melting point (M.P) determination	78
3.13.2	Fourier transform infrared spectroscopy (FT-IR)	79
3.13.3	Nuclear magnetic resonance spectroscopy (NMR)	79
3.13.4	High-resolution mass spectrometry (HRMS)	79
3.14	General procedure for organic synthesis (AMS-1-19)	80
3.14.1	Reaction conditions	80
3.14.2	Product isolation and purification	81

3.14.3	Product identification and confirmation	81
3.15	Solid phase extraction mass spectrometry (SPE-MS) inhibition assays	98
3.15.1	SPE-MS-based inhibitory profiling of PHD2 and PHD3	99
3.15.2	Enzyme selectivity profiling against FIH, JMJD6, and KDM4A	100
3.16	Carr-Purcell-Meiboom-Gill (CPMG) NMR binding analysis	102
CHAPTER 4 <i>IN SILICO</i> SCREENING AND FREE ENERGY ANALYSIS OF NATURAL AND SYNTHETIC COMPOUND DATABASES FOR PROLYL HYDROXYLASE DOMAIN (PHD) INHIBITOR DISCOVERY		103
4.1	Background and objectives	103
4.2	Results and discussion	104
4.2.1	Database preparation and filtering	104
4.2.2	Docking Validation	104
4.2.3	Virtual screening and induced fit docking	105
4.2.4	Molecular dynamics simulations analysis of ligand-PHD2 complexes	112
4.2.4(a)	Root means square deviation (RMSD) analysis	112
4.2.4(b)	Radius of gyration (Rg) analysis	114
4.2.4(c)	Root mean square fluctuation (RMSF) analysis	115
4.2.4(d)	Hydrogen bond analysis	116
4.2.4(e)	Post-molecular dynamics hydrogen bonding analysis	117
4.2.4(f)	Solvent-accessible surface area (SASA) analysis	121
4.2.4(g)	Evaluation of the binding free energy	122
4.2.5	Molecular evaluation of lead compounds	123
4.2.6	ADMET evaluation of lead compounds	125
4.2.7	Structure-activity relationship (SAR) analysis	128

4.3	Conclusions and future directions.....	130
 CHAPTER 5 MOLECULAR DISCOVERY OF NATURAL PRODUCT- DERIVED INHIBITORS TARGETING HYPOXIA INDUCIBLE FACTOR PROLYL HYDROXYLASE (HIF-PHD) 131		
5.1	Background and objectives	131
5.2	Results and discussion	132
5.2.1	Database preparation and filtering.....	132
5.2.2	Docking validation.....	133
5.2.3	Virtual screening.....	133
5.2.4	Induced fit docking (IFD).....	134
5.2.5	Molecular dynamic simulations.....	140
5.2.5(a)	Dynamic stability analysis of the top hits by RMSD.....	140
5.2.5(b)	Protein structural packing through the radius of gyration (Rg) estimation.....	142
5.2.5(c)	Residues flexibility analysis as RMSF	143
5.2.5(d)	Hydrogen bonding and half-life estimation.....	144
5.2.5(e)	Binding free energy of the top hits	146
5.3	Structure-activity relationship (SAR)	148
5.4	Conclusions and future directions.....	150
 CHAPTER 6 INTEGRATED VIRTUAL SCREENING, MOLECULAR SIMULATIONS, AND AUTOQSAR MODELING FOR THE DISCOVERY OF PROLYL HYDROXYLASE DOMAIN (PHD) INHIBITORS FROM NATURAL AND SYNTHETIC COMPOUNDS 151		
6.1	Background and objectives	151
6.2	Results and discussion	152
6.2.1	Protein preparation.....	152
6.2.2	Database preparation and filtering.....	152
6.2.3	Docking validation.....	153

6.2.4	Virtual screening of databases	154
6.2.5	Induced fit docking (IFD)	154
6.2.6	Molecular dynamic simulation	160
6.2.6(a)	Dynamic stability analysis of PHD2-ligand complexes	160
6.2.6(b)	Fluctuation analysis of PHD2-ligand complexes at the residues level	161
6.2.6(c)	Compactness analysis of PHD2-ligand complexes	162
6.2.6(d)	Hydrogen bonding network analysis of PHD2-ligand complexes	163
6.2.6(e)	Binding free energy calculation of PHD2-ligand complexes	164
6.3	Deep AutoQSAR model and pIC ₅₀ Calculation	166
6.4	ADMET analysis.....	168
6.5	Conclusions	171
CHAPTER 7 DISCOVERY OF PROLYL HYDROXYLASE DOMAIN 2 (PHD2) INHIBITORS FROM THE ENAMINE REAL DATABASE VIA INTEGRATED <i>IN SILICO</i> AND <i>IN VITRO</i> METHODS		172
7.1	Background and objectives	172
7.2	Results and discussion	173
7.2.1	Dataset preparation	173
7.2.2	Protein preparation.....	174
7.2.3	Positive control-based docking validation.....	175
7.2.4	Hit selection from the REAL database of EnamineStore	176
7.2.5	Virtual screening.....	176
7.2.6	Induced fit docking (IFD)	177
7.2.6(a)	A. Isoquinoline-glycine scaffold compounds (1-6)	179

7.2.6(b)	Pyrazole-carboxylic acid derivatives (7-9).....	183
7.2.6(c)	Benzimidazole-carboxylic acid derivatives (10)	185
7.2.7	Molecular and drug likeness analysis	186
7.2.8	ADMET analysis	190
7.3	<i>In vitro</i> PHD2 inhibition analysis using SPE-MS assay	194
7.4	Structure-activity relationship (SAR) analysis.....	197
7.5	Conclusions	199
CHAPTER 8 <i>IN SILICO</i> AND <i>IN VITRO</i> EVALUATION OF NEWLY SYNTHESIZED CARBAMOYL DERIVATIVES AS PROLYL HYDROXYLASE DOMAIN (PHD) INHIBITORS		200
8.1	Introduction	200
8.2	<i>In silico</i> studies.....	201
8.2.1	Re-docking of positive control	201
8.2.2	Chemical design of carbamoyl derivatives (CDs).....	202
8.2.3	Docking evaluation of carbamoyl derivatives (CDs)	204
8.3	Synthesis of carbamoyl derivatives (1-18).....	216
8.4	Characterization of Carbamoyl derivatives (CDs).....	218
8.4.1	Physical properties and HRMS analysis of CDs (AMS-1-AMS-19).....	218
8.4.2	FT-IR analysis of CDs (AMS-1 to AMS-19)	222
8.4.3	NMR analysis of CDs (AMS-1-AMS-19).....	225
8.5	<i>In vitro</i> inhibitory profiling of CDs (AMS-1-AMS-19).....	240
8.5.1	SPE-MS-based inhibitory profiling of PHD2 and PHD3	241
8.5.2	Enzyme selectivity profiling against FIH, JMJD6, and KDM4A	243
8.6	CPMG NMR binding analysis for AMS-12.....	245
8.7	Conclusions	247

CHAPTER 9 CONCLUSIONS AND FUTURE DIRECTIONS	249
9.1 Conclusions	249
9.2 Future Directions.....	251
REFERENCES.....	253
APPENDICES	
LIST OF PUBLICATIONS	

LIST OF TABLES

	Page
Table 1.1 Some of key 2OGXs ,their function and relevant diseases (Fletcher et al., 2020; Yang et al., 2024).....	12
Table 2.1 Chronological evolution of HIF research: Milestones from 1995 to 2025 (Saber et al., 2025; Soni et al., 2017; Zhang et al., 2024).	26
Table 2.2 IC ₅₀ (μM) values of different metal ions against different PHD isoforms.....	31
Table 2.3 FDA-approved drugs developed using CADD and their therapeutic uses (Vemula et al., 2023).	58
Table 2.4 Challenges and limitations in CADD (Shah et al., 2022).	60
Table 3.1 Summary of compound databases and libraries used across Chapters 4-8, including source, number of compounds, preparation and docking tools, and filtering criteria, RO5.....	70
Table 4.1 2D structures of the top hits and control ligand with their names, database IDs, docking scores, interacting residues, and interaction nature.....	106
Table 4.2 Scaffold comparison of top hits showing distinct core structures, Fe ²⁺ chelation motifs, and key residue interactions (Arg383, Tyr329). The chemical diversity supports potential for SAR-based optimization.	111
Table 4.3 Binding free energy calculation using the MM-GBSA approach. All the results are given in kcal/mol.....	123
Table 4.4 Molecular properties of the identified hits using pkCSM.....	125
Table 4.5 ADMET properties of the identified hits using pkCSM.	127
Table 4.6 SAR summary of top four hits and control (Vadadustat), highlighting key functional groups, docking scores, Fe ²⁺ coordination, and interactions with PHD2 active site residues.....	129
Table 5.1 Top 10 hit compounds with docking scores and source databases.	134

Table 5.2	2D structures of the top hits and control ligand with their names, database IDs, docking scores, interacting residues and nature are given.	135
Table 5.3	Hydrogen bonding information of the essential active site residues. The table shows the % of consistency of a particular hydrogen bond with the calculated frames during the simulation.....	146
Table 5.4	Total binding free energy for each complex calculated using the simulation trajectories.	147
Table 5.5	SAR analysis of the four top hits natural product-derived compounds and control (4HG), highlighting key ligand functional groups involved in Fe ²⁺ coordination, hydrogen bonding, and π - π interactions, along with corresponding docking scores.....	149
Table 6.1	Features of the top hit compounds, including their database IDs, names, structures, docking scores, interacting residues, bond distances, and the nature of their interactions within the PHD2 active site.....	155
Table 6.2	Binding free energies calculated for PHD2-ligand complexes.....	165
Table 6.3	Top ten models from the AutoQSAR used to predict the pIC ₅₀ values of the top hits.	167
Table 6.4	Predicted pIC ₅₀ values of the top hit compounds from QSAR analysis.....	167
Table 6.5	ADMET properties of the top hit compounds assessed using the admetSAR server. (p= probability, + = yes and - = no).....	169
Table 6.6	AMES toxicity, carcinogenicity, biodegradation, and acute oral toxicity of the top hit compounds. (p= probability, + = yes and - = no).....	170
Table 7.1	Selected PHD2 protein crystal structures along with their bound ligands and corresponding resolutions.	174
Table 7.2	Compound IDs, docking scores, interacting residues, binding interactions, and functional group characteristics of the top ten hits with PHD2 (2G19).	178
Table 7.3	Molecular and drug likeness analysis of the lead compounds.	189
Table 7.4	ADMET properties of lead compounds.	193

Table 8.1	Physicochemical properties and Lipinski's Rule of Five (RO5) compliance for AMS-1 to AMS-19	203
Table 8.2	Docking scores, key interacting residues, and interaction profiles of carbamoyl derivatives in PHD2 (2G19). (<i>MB=metallic bond, HB hydrogen bond</i>)	205
Table 8.3	The physical and HRMS spectral data for the CDs (AMS-1 to AMS-19), detailing their molecular formulas (MF), appearances, melting points (M.P), measured masses (MM), calculated masses (CM), actual yields (AY), and percentage yields (% Y).	221
Table 8.4	FT-IR spectral data of the carbamoyl derivatives (CDs) (AMS-1 to AMS-19)	224
Table 8.5	Detailed summary of ¹ H-NMR and ¹³ C-NMR spectral data of CDs (AMS-1 to AMS19).....	228
Table 8.6	The proton-carbon correlations based on the HSQC spectrum, with each H linked to the corresponding C and the Description.....	234
Table 8.7	The proton-proton correlations based on the COSY spectrum, with each proton (H) in relation to neighbors proton and the Description	236
Table 8.8	The proton-carbon correlations based on the HMBC spectrum, with each H linked to the corresponding C and the Description.....	239
Table 8.9	The SPE-MS inhibitory studies of synthesized CDs against PHD2 and PHD3. (<i>NI= no inhibition</i>). The table summarizes the half-maximal inhibitory concentration (IC ₅₀) values of AMS-1 to AMS19 against PHD2, as well as their percentage inhibition (% I) of PHD3 at two fixed concentrations (20 μM and 50 μM). 2,4-Pyridinedicarboxylic acid (2,4-PDCA) is included as a positive control.....	243
Table 8.10	The selectivity studies of synthesized CDs against FIH, KDM4A and JMJD6. (<i>NI= no inhibition</i>). The table presents the IC ₅₀ values (μM) of AMS compounds against FIH, KDM4A, and JMJD6 to assess off-target activity. 2,4-Pyridinedicarboxylic acid (2,4-PDCA) is used as a positive control.	245

LIST OF FIGURES

	Page
Figure 1.1	Structure of human HIF-1α: The schematic depicts key structural domains of HIF-1α involved in DNA binding, dimerization, ARNT interaction, and transcriptional regulation under hypoxic conditions. The basic helix-loop-helix (bHLH) and PAS (PER-ARNT-SIM) domains at the N-terminus mediates heterodimerization with HIF-β (ARNT) and recognition of hypoxia response elements (HREs) on target DNA. These domains are essential for DNA binding and the formation of a functional transcriptional complex. The N-terminal oxygen-dependent degradation domain (NODD) and C-terminal oxygen-dependent degradation domain (CODD) control protein stability through prolyl hydroxylation in normoxia. The N-terminal transactivation domain (NAD) and C-terminal transactivation domain (CAD) contribute to transactivation of hypoxia inducible genes and are also regulated by post-translational modifications and protein-protein interactions (Fernández et al., 2017).....
	5
Figure 1.2	Hydroxylation of HIF-1α by PHDs and FIH, utilizing Fe (II), 2OG, and oxygen, results in proline/asparagine hydroxylation, with succinate and CO₂ as byproducts, crucial for regulating HIF stability and hypoxic response.....
	7
Figure 1.3	Schematic of 2OGDD enzyme-catalyzed hydroxylation, where Fe²⁺, 2OG, and O₂ drive sequential binding and oxidation, leading to Fe (IV)-oxo formation, substrate hydroxylation, and succinate release as a byproduct (Islam, et al., 2018a).
	7
Figure 1.4	HIF-α levels are regulated by oxygen-dependent enzymes prolyl hydroxylase (PHD) and factor inhibiting HIF (FIH). Under normoxic conditions, HIF-1α is hydroxylated at Pro402 and/or Pro564, leading to pVHL-mediated proteasomal degradation. Additionally, hydroxylation at Asn803 by FIH prevents its interaction with the co-activator p300/CBP, suppressing transcriptional activity. In hypoxia, hydroxylase activity is reduced, allowing HIF-α to stabilize, dimerize with HIF-β, bind hypoxia response elements (HREs), recruit p300/CBP, and activate transcription. Adapted from Schofield <i>et al</i> (Schofield et al., 2004).
	8
Figure 1.5	2OG binding within the PHD2 active site. A) Structural view of PHD2 accommodating 2OG. B) 3D illustration showing 2OG chelating the Fe (II) center and interacting with key residues

	Arg383 and Tyr329 (Chowdhury et al., 2020) (PDB: 3OUJ) (Rosen et al., 2010).	9
Figure 1.6	Overall structure of the 2OG oxygenases. A) General 2-dimensional topology of a 2OG oxygenase. B) Three-dimensional representation of the 2OG oxygenase fold adapted from a crystal structure of AlkB (PDB ID: 3BIE) (Aik et al., 2015).	11
Figure 1.7	Functional grouping of 2OG oxygenases (2OGXs) by substrate type and function: Collagen hydroxylases (green), nucleotide hydroxylases (blue), translation factor/ribosomal protein hydroxylases (light blue), protein hydroxylases (yellow), and JmjC histone lysine demethylases (gray). Key enzymes like TET1-3, PHD1-3, FIH, and various KDMs highlight their roles in nucleotide, HIF, and histone regulation (Fletcher et al., 2020).	12
Figure 1.8	Sequence alignment of human PHD1-3 (Flashman et al., 2008). Asterisks (*) denote highly conserved residues, colons (:) indicate moderately conserved residues, and periods (.) represent the least conserved residues. The alignment was generated using ClustalX 2.1 software.....	15
Figure 1.9	Stereo view ribbon diagram depicting the secondary structure of the catalytic domain of PHD2, which is bound to the 2-[(4-hydroxy-8-iodoisoquinolin-3-yl)formamido]acetic acid (4HG) (highlighted in green). The active site Fe (II) ion is represented as an orange sphere (PDB ID: 2G19) (McDonough et al., 2006).	17
Figure 2.1	Transcriptional targets regulated by HIFs and their role in cancer cell metabolism and therapy (Jochmanová et al., 2013).....	28
Figure 2.2	Summary of the major classes of PHD inhibitors discussed in this review.	30
Figure 2.3	Iron chelators as PHD inhibitors.....	32
Figure 2.4	2OG binding within the PHD2 active site. A) Structural view of PHD2 accommodating 2OG. B) 3D illustration showing 2OG chelating the Fe (II) center and interacting with key residues Arg383 and Tyr329 (PDB 3OUJ) (Rosen et al., 2010).....	33
Figure 2.5	Early carboxylic acid-based inhibitors (CABPIs).....	34
Figure 2.6	N-oxalylglycine (NOG) binding within the PHD2 active site. A) Structural view of PHD2 accommodating NOG. B) 3D illustration showing NOG chelating the active site Mn (II)	

	center and interacting with key residues Arg383 and Tyr329 (PDB 5L9R) (Chowdhury et al., 2016).....	34
Figure 2.7	Key scaffolds used in modern classes of CABPIs	35
Figure 2.8	Structures of isoquinoline derivatives reported as CABPIs.....	36
Figure 2.9	BIQ binding within the PHD2 active site. A) Structural view of PHD2 accommodating BIQ. B) 3D illustration showing BIQ chelating the active site Mn (II) center and interacting with key residues Tyr303, Arg383 and Tyr329 (PDB 5LB6) (Chowdhury et al., 2016).....	37
Figure 2.10	Structures of pyridines derivatives as CABPIs	38
Figure 2.11	Vadadustat binding within the PHD2 active site. A) Structural view of PHD2 accommodating Vadadustat. B) 3D illustration showing Vadadustat chelating the Mn (II) center and interacting with key residues Tyr303, Arg383 and Tyr329. (PDB 5OX6) (Yeh et al., 2017).....	38
Figure 2.12	Structures of quinolones and pyridone derivatives reported as CABPIs	39
Figure 2.13	Re-docked Desidustat binding within the PHD2 (2G19) active site. A) Structural view of PHD2 accommodating Desidustat. B) 3D illustration showing Desidustat chelating the Fe (II) center and interacting with key residues Tyr303, Arg383 and Tyr329 (Corner et al., 2024).	40
Figure 2.14	Structures of triazolopyridine derivatives as CABPIs	41
Figure 2.15	Docked binding models of compound 36 and electrostatic map of 5,6-fused rings A) Docked binding models (I and II) of compound 36 within PHD2 active site. B) Electrostatic potential map of 5,6-fused rings, showing positive (blue), negative (red), and neutral (white) charges. The pyridine moiety is outlined in green (Ogoshi et al., 2017).	42
Figure 2.16	Re-docked Enarodustat binding within the PHD2 (PDB 2G19) active site. A) Structural view of PHD2 accommodating Enarodustat. B) 3D illustration showing Enarodustat chelating the Fe (II) center and interacting with key residues Arg383 and Tyr329.....	42
Figure 2.17	Structures of benzimidazole derivatives reported as CABPIs	43
Figure 2.18	X-ray co-crystal structures of benzimidazole derivatives within PHD2 active site. A) Structural view of PHD2 accommodating 40787422 (PDB 3OUI) and B) Structural view of PHD2	

	accommodating JNJ41536014 (PDB 3OUH) (Rosen et al., 2010).	44
Figure 2.19	Structures of pyrimidine and related derivatives reported as CABPIs	45
Figure 2.20	Key scaffolds used in modern classes of NCABPIs.	46
Figure 2.21	Structures of quinazoline and pyridone derivatives reported as NCABPIs.	47
Figure 2.22	Structures of pyrimidine derivatives reported as NCABPIs.	48
Figure 2.23	Structures of spiroindolones and spirohydantoin derivatives reported as NCABPIs.....	49
Figure 2.24	X-ray co-crystal structures of 4JR binding within the PHD2 active site. A) Structural view of PHD2 accommodating 4JR. B) 3D illustration showing 4JR chelating the Ni (II) center and interacting with key residues Arg322. (PDB 4JZR) (Deng et al., 2013)	49
Figure 2.25	X-ray co-crystal structures JPHM-2-167 binding within the PHD2 active site. A) Structural view of PHD2 accommodating JPHM-2-167. B) 3D illustration showing JPHM-2-167 chelating the Mn (II) center and interacting with key residues Arg322. (PDB 6QGV) (Holt-Martyn et al., 2019).....	50
Figure 2.26	Structures of pyrazole and pyrazolone derivatives reported as NCABPIs.	51
Figure 2.27	Molidustat binding within the PHD2 active site. A) Structural view of PHD2 accommodating Molidustat . B) 3D illustration showing Molidustat chelating the Mn (II) center and interacting with key residues Arg322. (PDB 6ZBO) (Figg Jr et al., 2021).	52
Figure 2.28	IOX4 binding within the PHD2 active site. A) Structural view of PHD2 accommodating IOX4. B) 3D illustration showing IOX4 chelating the Mn (II) center and interacting with key residues Arg322. (PDB 6ZBN) (Figg Jr et al., 2021).	52
Figure 2.29	Structures of triazole and thiazole derivatives reported as NCABPIs.	53
Figure 2.30	Binding of 76 analogue within the PHD2 active site. A) Structural view of PHD2 accommodating 76 analogue. B) 3D illustration showing 76 analogue chelating the Fe (II) center and interacting with key residues Arg322, Ly408, Tyr303, Tyr329 and Arg383. (PDB 4KBZ) (Hong et al., 2014).....	54

Figure 2.31	Non-conventional PHD inhibitors reported as NCPIs	55
Figure 2.32	Binding of 8UY within the PHD1 active site. A) Structural view of PHD2 accommodating 8UY. B) Stereo view of 8UY binding, showing monodentate Fe ²⁺ coordination and hydrogen bonding with Asn315. (PDB 5V1B) (Ahmed et al., 2017).....	55
Figure 2.33	Structures of FDA-approved drugs developed using CADD.....	58
Figure 2.34	The key role of amide bonds in the structural design and potency of various drugs including clinical trial PHD2 inhibitors.	63
Figure 2.35	Structures of 3CA derivatives as PHD2 inhibitors	64
Figure 3.1	Complete workflow employed in this study.	66
Figure 3.2	Structure of 4HG, Roxadustat, Vadadustat, and Desidustat used as positive controls for molecular studies.	67
Figure 3.3	Structures of the synthesized carbamoyl derivatives (CDs).	82
Figure 4.1	Superimposed illustration of Re docked Vadadustat (AKB-6548) on PHD2 (2G19) validates docking accuracy. (A) Aligned cartoon representation of Vadadustat-2G19 (orange) on co-crystal 4HG-PHD2 (cyne) confirms structural alignment. (B) 3D overlay with RMSD 0.285 Å, ensuring reliability.....	105
Figure 4.2	Interaction patterns of positive control, Vadadustat in the PHD2 active Site A) 2D interaction pattern of Vadadustat, within the PHD2 active site. B) 3D interaction pattern of control, Vadadustat highlighting bidentate coordination with the active site iron ion (orange sphere) and key hydrogen bonding interactions with residues Arg383, Tyr329, and Tyr303 in the PHD2 active site.....	105
Figure 4.3	Interaction pattern of ZINC36378940 and ZINC2005305 with PHD2. A) 2D interaction pattern of ZINC36378940 with PHD2 B) 3D interaction pattern ZINC36378940 with PHD2. C) 2D interaction pattern of ZINC2005305 with PHD2 D) 3D interaction pattern ZINC2005305 with PHD2.	108
Figure 4.4	Interaction pattern of ZINC31164438 and ZINC67910437 with PHD2. A) 2D interaction pattern of ZINC31164438 with PHD2 B) 3D interaction pattern ZINC31164438 with PHD2. C) 2D interaction pattern of ZINC67910437 with PHD2 D) 3D interaction pattern ZINC67910437 with PHD2.	110
Figure 4.5	Iron chelation and salt bridge formation of Arg383 by 2OG, NOG, and Daprodustat in the PHD2 active site. A) Salt bridge	

	formation involving Arg383 by the carboxylate group of 2OG and NOG. B) Iron chelation via the carbonyl oxygens of Daprodustat.	110
Figure 4.6	Core scaffold comparison of the top hits, highlighting structural diversity and shared Fe ²⁺ chelation and key residue interactions (Arg383, Tyr329).	112
Figure 4.7	Stability analysis of ligand-PHD2 complexes by RMSD calculation. A) RMSD value of the ZINC36378940-PHD2 complex. B) RMSD value of the ZINC2005305-PHD2 complex. C) RMSD value of ZINC31164438-PHD2 complex. D) RMSD value of the control AKB-6548-PHD2 complex.	113
Figure 4.8	Compactness analysis of ligand-PHD2 complexes by Rg calculation. A) Rg value of the ZINC36378940-PHD2 complex. B) Rg value of the ZINC2005305-PHD2 complex. C) Rg value of ZINC31164438-PHD2 complex. D) Rg value of control AKB-6548-PHD2 complex.	114
Figure 4.9	Residual fluctuation analysis of ligands-PHD2 complexes by calculating RMSF.	115
Figure 4.10	The average hydrogen bonding analysis of lead drugs-PHD2 complexes. A) Number of hydrogen bonds in the ZINC36378940-PHD2 complex. B) Number of hydrogen bonds in the ZINC2005305-PHD2 complex. C) Number of hydrogen bonds in the ZINC31164438-PHD2 complex. D) Number of hydrogen bonds in control AKB-6548-PHD2 complex.	117
Figure 4.11	Post simulation interaction pattern A) 2D interaction pattern of ZINC36378940 with PHD2 B) 3D interaction pattern of ZINC36378940 with PHD2 C) 2D interaction pattern of ZINC2005305 with PHD2 D) 2D interaction pattern of ZINC2005305 with PHD2.	119
Figure 4.12	Post simulation interaction pattern A) 2D interaction pattern of ZINC31164438 with PHD2 B) 3D interaction pattern of ZINC31164438 with PHD2 C) 2D interaction pattern of control AKB-6548 with PHD2 D) 3D interaction pattern of control AKB-6548 with PHD2.	120
Figure 4.13	The solvent-accessible surface area (SASA) analysis over 100 ns MD of lead ligands-PHD2 complexes. A) Number of SASA of ZINC36378940-PHD2 complex. B) SASA of the ZINC2005305-PHD2 complex. C) SASA of the ZINC31164438-PHD2 complex. D) SASA of control AKB-6548-PHD2 complex.	122

Figure 5.1	Workflow adopted in the current work.	132
Figure 5.2	The docking pose of 2-[(4-hydroxy-8-iodoisoquinolin-3-yl)formamido]acetic acid (4HG), in PHD2 active site interacting with Fe ²⁺ and several key residues. A) Cartoon representation PHD2 having active site Fe ⁺² (orange sphere) and re-docked 4HG (pink). B) The 3D interaction of re-docked 4HG chelating Fe ⁺² and interacting with the active site residues of PHD2 i.e. Arg383, Tyr329 and Tyr303. (PDB ID: 2G19).	133
Figure 5.3	The docking pose of Distomadine B CMNPD13808 (1) in PHD2 active site interacting with Fe ²⁺ and several key residues. A) Cartoon representation of PHD2 having active site Fe ⁺² (orange sphere) and docked CMNPD13808 (1) (cyans). B) The 3D interaction of docked CMNPD13808 (1) (cyans) chelating Fe ⁺² and interacting with the active site residues of PHD2, i.e., Thr387, Arg322, Arg383 and Tyr329.	136
Figure 5.4	The docking pose of Boeravinone D, CID15081178 (2) in PHD2 active site interacting with Fe ²⁺ and several key residues. A) Cartoon representation of the PHD2 having active site Fe ⁺² (orange sphere) and docked CID15081178 (2) (cyans). B) The 3D interaction of re-docked CID15081178 (2) (cyans) chelating Fe ⁺² and interacting with the active site residues of PHD2, i.e., Gln329, Tyr303, Arg383 and Tyr329.	137
Figure 5.5	The docking pose of 3-debromolatondaine B methyl ester (CID71496944 (3)), in PHD2 active site interacting with Fe ²⁺ and several key residues. A) Cartoon representation of PHD2 having active site Fe ⁺² (orange sphere) and docked CID71496944 (3) (cyans). B) The 3D interaction of docked CID71496944 (3) (cyans) chelating Fe ⁺² and interacting with the active site residues of PHD2, i.e., Gln239, Tyr303, and Asp254.	138
Figure 5.6	The docking pose of Des- <i>N</i> methylxestomanzamine A, (CID11821407 (4)), in PHD2 active site interacting with Fe ²⁺ and several key residues. A) Cartoon representation of PHD2 having active site Fe ⁺² (orange sphere) and docked CID11821407 (4) (cyans). B) The 3D interaction of docked CID11821407 (4) (cyans) chelating Fe ⁺² and interacting with the active site residues of PHD2, i.e., Thr387, Tyr303, Arg383 and Tyr329.	139
Figure 5.7	Stability of the ligand-bound protein complexes in solvated model. A) RMSD for PHD2-CMNPD13808 (1). B) RMSD for PHD2-CID15081178 (2). C) RMSD for PHD2-CID71496944 (3). D) RMSD for PHD2-CID11821407 (4).	142

Figure 5.8	Rg analysis of the ligand-bound protein complexes in the solvated model. A) The Rg for PHD2-CMNPD13808 (1) is demonstrated. B) The Rg for PHD2-CID15081178 (2) is demonstrated. The Rg for PHD2-CID71496944 (3) is demonstrated. D) The Rg for PHD2-CID11821407 (4) is demonstrated.	143
Figure 5.9	Residue's flexibility analysis of the PHD2-CMNPD13808 (1), PHD2-CID15081178 (2), PHD2-CID71496944 (3), and PHD2-CID11821407 (4) complexes in a solvated model.	144
Figure 5.10	Hydrogen bonding analysis of the ligand-bound protein complexes in the solvated model. A) The H-bonds graph for PHD2-CMNPD13808 (1). B) The H-bonds graph for PHD2-CID15081178 (2). C) The H-bonds graph for PHD2-CID71496944 (3). D) The H-bonds graph for PHD2-CID11821407 (4).	146
Figure 6.1	Workflow adopted in the current work.	152
Figure 6.2	A) 3D detailed interactions representation of redocked control, Roxadustat (FG2216) (green) within the PHD2 active site. B) 3D aligned representation redocked Roxadustat (FG2216) (purple) on of co-crystal structure (2G19, cyan) on showing RMSD of 0.281.	153
Figure 6.3	2D (left) and 3D (right) docked poses with detailed interactions of ZINC02104411 in the PHD2 active site.	156
Figure 6.4	2D (left) and 3D (right) docked poses with detailed interactions of ZINC19850111 in PHD2 active site	157
Figure 6.5	2D (left) and 3D (right) docked poses with detailed interactions of ZINC04084230 in the PHD2 active site.	158
Figure 6.6	2D (left) and 3D (right) docked poses with detailed interactions of A) ZINC06645557 and B) ZINC02098727 in the PHD2 active site.	159
Figure 6.7	Dynamics stability analysis of PHD2-ligand complexes. Showing RMSD value of A) PHD2-FG4592, B) PHD2-ZINC02104411, C) PHD2-ZINC19850111, D) PHD2-ZINC04084230 complex.	161
Figure 6.8	Residual fluctuation analysis of PHD2-ligand complexes in comparison with control.	162
Figure 6.9	Compactness analysis of PHD2-ligand complexes. Images show the Rg values of A) PHD2-FG4592, B) PHD2-	

	ZINC02104411, C) PHD2-ZINC19850111, and D) PHD2-ZINC04084230 complexes.	163
Figure 6.10	Hydrogen bonding network analysis of PHD2-ligand complexes. Representing average hydrogen bonds of A) PHD2-FG4592, B) PHD2-ZINC02104411, C) PHD2-ZINC19850111, and D) PHD2-ZINC04084230 complex.	164
Figure 6.11	Predicted versus actual IC ₅₀ values for the test and training sets of top 10 models.....	168
Figure 7.1	Study design and workflow of the current work.....	173
Figure 7.2	The structures of the bound ligands, along with their corresponding PDB IDs (in parentheses), were retrieved from various PHD2 crystallographic structures.....	174
Figure 7.3	Superimposed illustration of docked Desidustat (ZYAN1) on PHD2 (2G19) validates docking accuracy. (A) Aligned cartoon representation of Desidustat-2G19 (cyan) on co-crystal 4HG-PHD2 (pink) confirms structural alignment. (B) 3D overlay with RMSD 0.214 Å shows minimal residue flexibility, ensuring reliability (Corner et al., 2022).....	175
Figure 7.4	2D (Left) and 3D (right) interaction pattern of Desidustat (ZYAN1) (green) in PHD2.	176
Figure 7.5	Top ten identified hits from REAL database of EnamineStore.	177
Figure 7.6	2D (left) and 3D (right) docked poses of A) PV-002764855062 (1) and B) PV-002750052388 (2) in the PHD2 active site.	180
Figure 7.7	2D (left) and 3D (right) docked poses of A) Z2802861059 (3) B) Z2647306699 (4) C) Z6039105031 (5) D) Z2910685095 (6) in the PHD2 active site.....	182
Figure 7.8	2D (left) and 3D (right) docked poses of A) PV-007248920550 (7) B) PV-006776228189 (8) C) PV-006733875884 (9) in the PHD2 active site.....	184
Figure 7.9	General structure of aza-benzimidazole analogues (left) and Binding mode of aza-benzimidazole analogues in the PHD2 active site (right) (Frohn et al., 2008)	185
Figure 7.10	2D (left) and 3D (right) docked poses of Z6742136823 (10) in the PHD2 active site.....	186
Figure 8.1	A) 3D interactions of re-docked 4HG (pink) with PHD2 (2G19), showing iron chelation and hydrogen bonding with Tyr303, Tyr329, and Arg383. B) Structural alignment of	

	redocked 4HG (pink) on crystal structure PHD2 (cyan), with an RMSD of 0.214 Å, indicating high docking accuracy with minimal residue flexibility.	202
Figure 8.2	Chemical structures of the carbamoyl derivatives (AMS-1 to AMS-19).	204
Figure 8.3	2D (left) and 3D (right) interaction profiles of A) AMS-1 , B) AMS-2 and C) AMS-3 in the PHD2 active site.	208
Figure 8.4	2D (left) and 3D (right) interaction profile of A) AMS-4 , B) AMS-5 and C) AMS-6 in PHD2 active site.	209
Figure 8.5	2D (left) and 3D (right) interaction profile of A) AMS-7 , B) AMS-8 and C) AMS-9 in PHD2 active site.	210
Figure 8.6	2D (left) and 3D (right) interaction profile of A) AMS-10 , B) AMS-11 and in PHD2 active site.	211
Figure 8.7	2D (left) and 3D (right) interaction profile of A) AMS-12 and B) AMS-13 in PHD2 active site.	212
Figure 8.8	2D (left) and 3D (right) interaction profile of A) AMS-14 , B) AMS-15 and in PHD2 active site.	213
Figure 8.9	2D (left) and 3D (right) interaction profile of A) AMS-16 and B) AMS-17 in PHD2 active site.	214
Figure 8.10	2D (left) and 3D (right) interaction profile of A) AMS-18 , B) AMS-19 and in PHD2 active site.	215
Figure 8.11	ESI-HRMS spectrum of AMS-1	220
Figure 8.12	ESI-HRMS spectrum of AMS-6	220
Figure 8.13	ESI-HRMS spectrum of AMS-12	220
Figure 8.14	FT-IR spectrum of AMS-1	223
Figure 8.15	FT-IR spectrum of AMS-8	223
Figure 8.16	FT-IR spectrum of AMS-12	223
Figure 8.17	Showing key protons and carbons of synthesized CDs	227
Figure 8.18	¹ H-NMR spectrum of AMS-1 in DMSO-d ₆	229
Figure 8.19	¹³ C-NMR spectrum of AMS-1 in DMSO-d ₆ ,	230
Figure 8.20	¹ H-NMR spectrum of AMS-9 in DMSO-d ₆	231

Figure 8.21	^{13}C -NMR spectrum of AMS-9 in DMSO- d_6	231
Figure 8.22	^1H -NMR spectrum of AMS-12 in DMSO- d_6	232
Figure 8.23	^{13}C -NMR spectrum of AMS-12 in DMSO- d_6	233
Figure 8.24	^1H - ^{13}C HSQC spectrum of compound 12 in DMSO- d_6	235
Figure 8.25	^1H - ^1H COSY spectrum of AMS-12 in DMSO- d_6	237
Figure 8.26	Hetero Multi Bond connectivity (HMBC) illustration of AMS-12	239
Figure 8.27	^1H - ^{13}C HMBC spectrum of AMS-12 in DMSO- d_6	239
Figure 8.28	Schematic of the CPMG NMR binding assay. Binding of the 2-OG substrate to PHD2 broadens its ^1H NMR resonance, reducing signal intensity. Introduction of a competitive ligand, exemplified here by AMS-12, displaces 2-OG from the active site, restoring the resonance signal (Leung et al., 2013).	246
Figure 8.29	CPMG NMR binding assay demonstrating displacement of 2-OG from the 2-OG/PHD2 complex by AMS-12 . A) Conventional ^1H NMR and B) CPMG-edited ^1H NMR analyses. The 2-OG methylene (CH_2) resonance at δH 2.36 ppm (■) was monitored as a readout for signal recovery.	247

LIST OF ABBREVIATIONS

2OG	2-oxoglutarate
2OGXs	2-oxoglutarate-dependent dioxygenases
ADMET	Absorption, distribution, metabolism, excretion, and toxicity
ANPDB	African Natural Products Database
AMES	Ames test for mutagenicity
ALK	Anaplastic lymphoma kinase
ACE	Angiotensin-converting enzyme
AI	Artificial intelligence
ARNT	Aryl hydrocarbon receptor nuclear translocator
AutoQSAR	Automated quantitative structure-activity relationship
BBB	Blood-brain barrier
CDs	Carbamoyl derivatives
AMS	Carbamoyl derivatives (AMS-1 to AMS-19)
CABPIs	Carboxylic acid-based PHD inhibitors
CVDs	Cardiovascular diseases
CPMG	Carr-Purcell-Meiboom-Gill (NMR binding analysis)
CNS	Central nervous system
CKD	Chronic kidney disease
CPPTRAJ	Command-line processing and programming trajectory
CMNPD	Comprehensive Marine Natural Products Database
CADD	Computer-aided drug design
CAD	C-terminal transactivation domain
CYP450	Cytochrome P450

DL	Deep learning
DVT	Deep venous thrombosis
EANPDB	East African Natural Products Database
ESI-HRMS	Electrospray ionization high-resolution mass spectrometry
EPO	Erythropoietin
XP	Extra precision docking
FIH	Factor inhibiting HIF
FGFR	Fibroblast growth factor receptors
FDA	Food and Drug Administration
FT-IR	Fourier transform-infrared spectroscopy
FAF-Drugs4	Free ADME-Tox filtering software for drug discovery
GAFF	General AMBER force field
IC ₅₀	Half maximal inhibitory concentration
HRMS	High-resolution mass spectrometry
HTS	High-throughput screening
HTVS	High-throughput virtual screening
HIA	Human intestinal absorption
HMG-CoA	Hydroxymethylglutaryl-CoA
HIF	Hypoxia inducible factor
IFD	Induced fit docking
ICAM-1	Intercellular adhesion molecule 1
JMJD6	Jumonji domain-containing protein 6
LBDD	Ligand-based drug design
RO5	Lipinski's Rule of Five
LFA-1	Lymphocyte function-associated antigen-1

KDM4A	Lysine-specific demethylase 4A
ML	Machine learning
MD	Molecular dynamics
MM/GBSA	Molecular mechanics/generalized Born surface area
4HG	N-[(4-Hydroxy-8-iodoisoquinolin-3-yl) carbonyl] glycine
NPACT	Naturally occurring plant-based anti-cancer compound-activity-target
pIC ₅₀	Negative logarithm of the half-maximal inhibitory concentration
NCABPIs	Non-carboxylic acid-based PHD inhibitors
NCPIs	Non-conventional PHD inhibitors
NSCLC	Non-small-cell lung cancer
NOG	N-oxalylglycine
NMR	Nuclear magnetic resonance spectroscopy
OPC	Optimal point charge
OCT	Organic cation transporter
ODD	Oxygen-dependent degradation domain
PAMPA	Parallel artificial membrane permeability assay
PME	Particle mesh Ewald
P-gp	P-glycoprotein
PK	Pharmacokinetics
pkCSM	Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signature
PHD	Prolyl hydroxylase domain
PDB	Protein Data Bank
PDBQT	Protein Data Bank, with charges and torsions

PPIs	Protein-protein interactions
QSAR	Quantitative structure-activity relationship
Rg	Radius of gyration
RCSB	Research Collaboratory for Structural Bioinformatics
RMSD	Root mean square deviation
RMSF	Root mean square fluctuation
RMSV	Root mean square variation
ROS1	ROS proto-oncogene 1
SNP	Single nucleotide polymorphism
SPE-MS	Solid phase extraction mass spectrometry
SASA	Solvent-accessible surface area
SANCDDB	South African Natural Compounds Database
SPMSM	Specific PHD2 hydroxylation assay
SAR	Structure-activity relationship
SBDD	Structure-based drug design
TPSA	Topological polar surface area
TIP3P	Transferable intermolecular potential with 3 points
2D-QSAR	Two-dimensional quantitative structure-activity relationship
UCSF	University of California, San Francisco
VEGF	Vascular endothelial growth factor
VDss	Volume of distribution at steady state
VHL	Von Hippel-Lindau
pVHL	Von Hippel-Lindau protein

LIST OF APPENDICES

Appendix A	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-1
Appendix B	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-2
Appendix C	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-3
Appendix D	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-4
Appendix E	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-5
Appendix F	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-6
Appendix G	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-7
Appendix H	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-8
Appendix I	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-9
Appendix J	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-10
Appendix K	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-11
Appendix L	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-12
Appendix M	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-13
Appendix N	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-14
Appendix O	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-15
Appendix P	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-16
Appendix Q	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-17
Appendix R	^1H NMR, ^{13}C NMR, FT-IR, and HRMS spectra of AMS-19

REKABENTUK, SINTESIS, PENILAIAN *IN SILICO* DAN *IN VITRO*
PERENCAT BAHARU YANG MENSASARKAN ENZIM PROLIL
HIDROKSILASE (PHD) FAKTOR PENDORONG HIPOKSIA MANUSIA
(HIF)

ABSTRAK

Enzim prolil hidroksilase (PHD) faktor pendorong hipoksia (HIF) memainkan peranan penting dalam pengesanan oksigen dan pengawalan, menjadikannya sasaran terapeutik utama bagi penyakit berkaitan hipoksia, termasuk penyakit kardiovaskular (CVD), penyakit buah pinggang kronik (CKD), dan anemia. Walau bagaimanapun, perencat PHD sedia ada mempunyai kelemahan yang ketara, termasuk ketoksikan, risiko tromboembolik, dan kekurangan selektiviti, yang memerlukan penemuan alternatif yang lebih selamat dan berkesan. Kajian ini menggunakan pendekatan gabungan komputasi-eksperimen untuk mengenal pasti perencat PHD yang baharu dengan mengintegrasikan dok molekul, simulasi dinamik molekul (MD), pengiraan tenaga bebas, pemodelan QSAR, dan pengesahan eksperimen. Satu set data yang terdiri daripada 147,583 sebatian semula jadi dan sintetik daripada pelbagai pangkalan data (AfroDb, CMNPD, NANPDB, NEANPDB, EANPDB, SANCDB, pangkalan data REAL EnamineStore, dan repositori berasaskan ZINC) telah ditapis menggunakan teknik *in silico* yang maju. Saringan maya (VS) yang diikuti dengan dok keserasian-teraruh (IFD) telah mengenal pasti beberapa calon berpotensi, termasuk ZINC36378940, ZINC02104411, CMNPD13808, dan Z6742136823, yang menunjukkan pertalian pengikatan yang unggul (-13.34 hingga -8.69 kcal/mol) serta interaksi stabil dengan residu tapak aktif yang kritikal (Tyr303, Arg383, Tyr329, Trp389). Calon terbaik daripada IFD kemudiannya dinilai lebih lanjut melalui simulasi

MD, yang mengesahkan kestabilan pengikatan mereka. Eksplorasi *in silico* dan *in vitro* terhadap sebatian daripada pangkalan data REAL EnamineStore telah mengenalpasti tujuh sebatian aktif, dengan Z6742136823 muncul sebagai perencat PHD2 yang menjanjikan (IC_{50} : 5.27 μ M). Dalam kajian ini, pelbagai rangka kimia yang berpotensi telah dikenal pasti, termasuk isoindol, pteridin, triterpenoid, spiro-isoindol, biflavonoid, kromon, β -laktam, indol, kuinolin, kromenon dan isoquinolin. Rangka-rangka ini menyediakan templat yang bernilai untuk reka bentuk masa hadapan perencat PHD. Selain itu, satu siri baharu terbitan karbamoil (CD) (**AMS-1** hingga **AMS-19**) telah didok, disintesis, dan dicirikan menggunakan FT-IR, NMR, dan HRMS. Meskipun keputusan dok *in silico* kelihatan menjanjikan, ujian enzim *in vitro* awal menunjukkan bahawa kebanyakan CD menunjukkan aktiviti perencatan yang lemah terhadap PHD2 dan PHD3, kecuali **AMS-12** yang menunjukkan perencatan berpotensi (PHD2 IC_{50} = 22.91 μ M; perencatan PHD3 = 76.42% pada 20 μ M). Pemprofilan kepekaan enzim selanjutnya mendedahkan bahawa **AMS-12** mempunyai perencatan lemah terhadap FIH (IC_{50} = 116.4 μ M) dan tiada aktiviti terhadap lisin demetilase 4A (KDM4A) atau protein yang mengandungi domain Jumonji 6 (JMJD6), terus menunjukkan kekhususannya. Analisis NMR Carr-Purcell-Meiboom-Gill (CPMG) menunjukkan bahawa **AMS-12** berkesan menyingkirkan ko-substrat 2-oksoglutarat (2OG) daripada PHD2, sekali gus mengesahkan potensi pengikatan kompetitifnya yang tinggi.

**DESIGN, SYNTHESIS, *IN SILICO* AND *IN VITRO* EVALUATIONS OF
NEW INHIBITORS TARGETING HUMAN HYPOXIA INDUCIBLE
FACTOR (HIF) PROLYL HYDROXYLASE DOMAIN (PHD) ENZYMES**

ABSTRACT

Hypoxia inducible factor (HIF) prolyl hydroxylase domain (PHD) enzymes play a pivotal role in oxygen sensing and regulation, making them key therapeutic targets for hypoxia-related diseases, including cardiovascular diseases (CVDs), chronic kidney disease (CKD), and anemia. However, current PHD inhibitors suffer from significant limitations, including toxicity, thromboembolic risks, and poor selectivity, necessitating the discovery of safer and more effective alternatives. This research utilises a computational-experimental methodology to discover new PHD inhibitors through the integration of molecular docking, molecular dynamics (MD) simulations, and free energy calculations, QSAR modeling, and experimental validation. A dataset of 147,583 natural and synthetic compounds from diverse databases (AfroDb, CMNPD, NANPDB, NEANPDB, EANPDB, SANCDB, the REAL database of EnamineStore, and ZINC-based repositories) was screened using advanced *in silico* techniques. Virtual screening (VS), followed by induced fit docking (IFD), identified several promising candidates, including ZINC36378940, ZINC02104411, CMNPD13808, and Z6742136823, which exhibited superior binding affinities (-13.34 to -8.69 kcal/mol) and stable interactions with critical active-site residues (Tyr303, Arg383, Tyr329, Trp389). The top hits from IFD were further evaluated through MD simulations, which confirmed their binding stability. *In silico* and *in vitro* exploration of compounds from the REAL database of EnamineStore further identified seven active compounds, with Z6742136823 emerging as a

promising PHD2 inhibitor ($IC_{50} = 5.27 \mu M$). Across these studies, multiple promising chemical scaffolds were discovered, including isoindole, pteridine, triterpenoid, spiro-isoindole, biflavonoid, chromone, β -lactam, indole, quinoline, chromenone and isoquinoline. These scaffolds provide valuable templates for the future design PHD inhibitors. Additionally, a novel series of carbamoyl derivatives (CDs) (**AMS-1** to **AMS-19**) was docked, synthesized, and characterized using FT-IR, NMR, and HRMS. Despite promising *in silico* docking results, preliminary *in vitro* enzyme assays showed that most CDs exhibited poor inhibitory activity against PHD2 and PHD3, except for **AMS-12**, which displayed potent inhibition (PHD2 $IC_{50} = 22.91 \mu M$; PHD3 inhibition = 76.42% at $20 \mu M$). Enzyme selectivity profiling further revealed that **AMS-12** had weak FIH inhibition ($IC_{50} = 116.4 \mu M$) and no activity against lysine demethylase 4A (KDM4A) or Jumonji domain-containing protein 6 (JMJD6), confirming its specificity. Carr-Purcell-Meiboom-Gill (CPMG) NMR analysis demonstrated that **AMS-12** effectively displaced the 2-oxoglutarate (2OG) co-substrate from PHD2, confirming its strong competitive binding potency.

CHAPTER 1

INTRODUCTION

1.1 Background

Hypoxia, a condition resulting from reduced oxygen availability triggers several cellular responses facilitated by hypoxia inducible factors (HIFs). Transcription factors significantly influence hypoxia signaling through the regulation of genes related to metabolism, angiogenesis, and erythropoiesis (Lee et al., 2020). The regulation of HIFs is largely controlled by enzymes known as prolyl hydroxylase domains (PHDs), which act as oxygen sensors (Hirota et al., 2021). These enzymes also hydroxylate HIFs under normal oxygen (O_2) levels, marking them for degradation (Taylor et al., 2022). PHDs are present in multiple isoforms and are expressed across various tissues, allowing them to play a significant role in oxygen sensing and adaptation (Lee et al., 2020).

The function of PHDs relies on the cofactor 2-oxoglutarate (2OG), as well as iron and oxygen, which are essential for PHD enzymatic activity (Fiorini et al., 2024). Recently, therapeutic targeting of PHDs has gained significant attention, with computer-aided drug design (CADD) playing a key role in these efforts (Sahlgren et al., 2017). The two primary and advanced techniques in CADD are ligand-based drug design (LBDD) and structure-based drug design (SBDD). However, despite the critical applications of CADD in drug discovery, challenges remain particularly in accurately predicting the behaviour of complex biological systems (Bharatam et al., 2021).

1.2 Hypoxia

Hypoxia, derived from the Greek words “*hypo*” (under) and “*oxia*” (oxygen), refers to a condition where a specific region of the body or the entire body is deprived of an adequate oxygen supply (Guo et al., 2019). Hypoxia can affect the entire body, known as generalized hypoxia, or it can impact specific tissues, referred to as tissue hypoxia, potentially leading to severe health consequences. Hypoxia may arise from insufficient oxygen delivery to the lungs, perhaps caused by multiple reasons. This encompasses respiratory ailments such as chronic obstructive pulmonary disease (COPD) and pneumonia, elevated altitudes, and circulatory disorders that hinder oxygen transfer in the bloodstream (Zhou et al., 2022). Additionally, it may occur when oxygen consumption exceeds normal levels, such as during exercise, infection, or increased metabolic activity, leading to systemic or localized oxygen deprivation (Choudhury et al., 2018).

Researchers, healthcare professionals, and scientists have been captivated by the profound impact of hypoxia on cellular activities and its relationship with a variety of diseases. This condition can arise from multiple factors, including environmental circumstances, various health states, or altered physiological processes, which disrupt the delicate balance between oxygen supply and consumption (Hasegawa et al., 2018; Masoud & Li, 2015; Zhang et al., 2011).

The investigation of hypoxia dates to the 18th century, with the first reports detailing the effects of altitude on human performance and health. In the early 1900s, Christian Bohr and colleagues introduced the concept of the oxygen dissociation curve in their groundbreaking research. This framework laid the foundation for our understanding of how haemoglobin binds and releases oxygen in response to changes

in partial pressure (Semenza et al.,1992). In 1991, Semenza and his team identified a hypoxia inducible enhancer situated upstream of the human erythropoietin gene in the kidneys and livers of transgenic mice subjected to functional hypoxia induced by anaemia. (Semenza et al.,1992). The nuclear factor identified as responsible for the enhanced gene expression observed in these experiments is referred to as hypoxia inducible factor (HIF). In response to hypoxia, cells initiate a series of adaptive changes aimed at maintaining cellular homeostasis and ensuring survival (Miikkulainen et al., 2019). The hypoxic response is primarily mediated by the HIF transcription factor family, which governs genes associated with angiogenesis, oxygen transport, energy metabolism, and apoptosis (Yang et al., 2016). When oxygen levels are low, HIF triggers a transcriptional response that induces adaptive changes in cellular activities, modifies energy production processes, and enhances oxygen transport. However, chronic or severe exposure to hypoxia can contribute to the development of several diseases, including cardiovascular diseases, neurological disorders and, cancer (Luo et al., 2022).

1.3 Hypoxia inducible factors (HIFs)

Hypoxia inducible factors (HIFs) are a small family of heterodimeric transcription factors consisting of three members: HIF-1, HIF-2, and HIF-3 (Foster et al., 2014). HIFs are primarily responsible for mediating the cellular effects of hypoxia. In 1992, Semenza and his postdoctoral researcher Wang demonstrated that these heterodimers comprise an oxygen-sensitive α -subunit and a stable β -subunit (Eales et al., 2016; Wang et al., 1993). Cellular responses to low oxygen levels are largely orchestrated by HIF, which activates genes involved in key processes such as metabolic reprogramming, and angiogenesis (Liberti et al.,2016). Additionally, HIF

regulates gene expression related to immunity, inflammation, stem cell maintenance, and tissue repair (Foster et al., 2014). HIF functions as a key mediator in various pathological and physiological processes, encompassing human development, wound healing, ischaemia, cancer, and chronic kidney disease (Braicu et al., 2019; Zappa et al., 2016).

1.4 The hypoxia signaling pathway

The activity of the HIF protein is predominantly governed by the transcriptional dynamics and stability of its α -subunits, namely HIF-1 α , HIF-2 α , and HIF-3 α . These activities are controlled in an oxygen-dependent manner through post-translational modifications (Miao et al., 2022). HIF-1 α exhibits widespread expression and is involved in various cellular processes, whereas HIF-2 α demonstrates a more specialised tissue distribution and specific functions, including the regulation of erythropoietin (EPO) synthesis in the liver (Tanaka et al., 2016). In contrast, HIF-3 α is less well understood, though it is known to negatively regulate the activities of HIF-1 α and HIF-2 α (Miao et al., 2022).

In normoxic conditions, two proline residues (Pro402 and Pro564 in human HIF- α subunits) in the oxygen-dependent degradation domains (ODDs) of HIF- α subunits undergo hydroxylation by PHD enzymes (PHD1-3). This hydroxylation designates HIF- α for ubiquitin-dependent degradation by the von Hippel-Lindau (VHL) E3 ligase complex. Figure 1.1 illustrates the structural of human HIF-1 α , highlighting the basic helix-loop-helix (bHLH), C-terminal transactivation domain (CAD), Per-ARNT-SIM (PAS), C-terminal oxygen-dependent degradation domain (Codd), nicotinamide adenine dinucleotide (NAD), and N-terminal oxygen-dependent degradation domain (Nodd) regions essential for its functional

interactions and regulation (Thévenod et al., 2022). Kaelin and his team were the pioneers in identifying that the VHL gene encodes the tumour suppressor protein pVHL, which is essential for regulating cellular responses to hypoxia (Hurst et al., 2016). Mutations in the VHL gene can prevent the degradation of HIF- α in normoxic conditions by bypassing the ubiquitination checkpoint, thus stabilizing HIF- α even when oxygen is present (Tirpe et al., 2019). Furthermore, an asparagine residue in the CAD of HIF- α (Asn803 in human HIF-1 α) undergoes hydroxylation by the factor inhibiting HIF (FIH) enzyme. This alteration obstructs the interaction of HIF- α with the coactivator p300/CBP, hence reducing its transcriptional function (Fantis et al., 2023). In 2003, Tanimoto *et al.* demonstrated that a single nucleotide polymorphism (SNP) in the HIF1A gene (rs11549465) results in the substitution of proline with serine at position 582 (P582S). This polymorphism increases the transcriptional activity of HIF-1 α by altering the properties of its binding sites and target genes (Javier et al., 2015; Javier et al., 2017; Fernández et al., 2017).




Figure 1.1 Structure of human HIF-1 α : The schematic depicts key structural domains of HIF-1 α involved in DNA binding, dimerization, ARNT interaction, and transcriptional regulation under hypoxic conditions. The basic helix-loop-helix (bHLH) and PAS (PER-ARNT-SIM) domains at the N-terminus mediates heterodimerization with HIF- β (ARNT) and recognition of hypoxia response elements (HREs) on target DNA. These domains are essential for DNA binding and the formation of a functional transcriptional complex. The N-terminal oxygen-dependent degradation domain (NODD) and C-terminal oxygen-dependent degradation domain (CODD) control protein stability through prolyl hydroxylation in normoxia. The N-terminal transactivation domain (NAD) and C-terminal transactivation domain (CAD) contribute to transactivation of hypoxia inducible genes and are also regulated by post-translational modifications and protein-protein interactions (Fernández et al., 2017).

The structural composition of human HIF-1 α includes the bHLH and PAS domains, which are crucial for binding with HIF- β and the hypoxia response element (HRE). It comprises NODD, CODD, NAD, and CAD. The PAS domain is also associated with the period circadian protein (PER), aryl hydrocarbon receptor nuclear translocator (ARNT), and single-minded protein (SIM) (Javier et al., 2017; J Fernández et al., 2017).

PHDs and FIH are dioxygenases that require Fe (II) and 2OG for their enzymatic activity. These enzymes use oxygen and 2OG as co-substrates, producing succinate, carbon dioxide, and hydroxylated residues as byproducts. Figure 1.2 depicts hydroxylation reactions mediated by PHDs and FIH, highlighting the dependence on Fe (II), 2OG, and oxygen, with hydroxylated residues, succinate, and CO₂ as end products (Cavadas et al., 2013). The proposed mechanism of 2OG and Fe (II)-dependent oxygenases is illustrated in Figure 1.3. It outlines the process observed in various 2OG-dependent oxygenase reactions (Islam et al., 2018b; Martinez et al., 2015). Initially, 2OG interacts with Fe (II), displacing two water molecules within the enzyme's active site. Oxygen then reacts with 2OG, forming succinate and Fe (IV)=O via oxidative decarboxylation. The Fe (IV)=O hydroxylates the peptide substrate through a radical mechanism, altering its structure. Finally, the hydroxylated peptide and succinate exit, and the enzyme returns to its resting state (Tarhonskaya et al., 2014).




Figure 1.2 Hydroxylation of HIF-1 α by PHDs and FIH, utilizing Fe (II), 2OG, and oxygen, results in proline/asparagine hydroxylation, with succinate and CO₂ as byproducts, crucial for regulating HIF stability and hypoxic response.




Figure 1.3 Schematic of 2OGDD enzyme-catalyzed hydroxylation, where Fe²⁺, 2OG, and O₂ drive sequential binding and oxidation, leading to Fe (IV)-oxo formation, substrate hydroxylation, and succinate release as a byproduct (Islam, et al., 2018a).

Figure 1.4 illustrates the modulation of HIF-1 α levels and activity in relation to oxygen supply. Under normoxic conditions, proline residues (Pro402/564) of HIF-1 α undergo hydroxylation by PHDs, resulting in pVHL-mediated ubiquitination and

subsequent destruction via the 26S proteasome. Additionally, FIH hydroxylates asparagine residue (Asn803), blocking p300/CBP coactivator binding and inhibiting transcriptional activation. In hypoxia, reduced hydroxylase activity stabilizes HIF-1 α , allowing dimerization with HIF-1 β , recruitment of p300/CBP, binding to HREs, and activation of target gene transcription. This leads to substrate phosphorylation, allowing HIF-1 β binds to HIF-1 α which activate target gene for the transcription (Drager et al., 2004).




Figure 1.4 HIF- α levels are regulated by oxygen-dependent enzymes prolyl hydroxylase (PHD) and factor inhibiting HIF (FIH). Under normoxic conditions, HIF-1 α is hydroxylated at Pro402 and/or Pro564, leading to pVHL-mediated proteasomal degradation. Additionally, hydroxylation at Asn803 by FIH prevents its interaction with the co-activator p300/CBP, suppressing transcriptional activity. In hypoxia, hydroxylase activity is reduced, allowing HIF- α to stabilize, dimerize with HIF- β , bind hypoxia response elements (HREs), recruit p300/CBP, and activate transcription. Adapted from Schofield *et al* (Schofield et al., 2004).

1.5 2-Oxoglutarate (2OG)

2-Oxoglutarate (2OG), also referred to as α -ketoglutarate or 2-oxopentanedioic acid, is a five-carbon molecule containing two carboxyl groups. It serves as an

essential cofactor for PHDs, which regulate the stability of HIF under normoxic conditions (Frost et al., 2021). The relationship between 2OG, PHDs, and HIF is crucial for cellular adaptation to fluctuating oxygen levels, helping to understand the molecular mechanisms behind hypoxia-related diseases and physiological responses. The enzymatic activity of PHD is dependent upon 2OG as a co-substrate (Bailey et al., 2020). Figure 1.5 depicts the co-crystal structure of 2OG with the PHD2 catalytic domain (PDB ID: 3OUJ). The structure indicates that the Fe (II) center is bidentately coordinated by the sp^2 oxygen atoms at C1 and C2 of 2OG. A salt bridge is present between the carboxylate group at C5 and Arg383, whereas a hydrogen bond is established between the hydroxyl group of Tyr329 phenol. The 2OG binding pocket is also surrounded by a cluster of hydrophobic residues, including Ile327, Ile256, Met299, Leu343, Trp389, Ala301, Ala365, and Val376 (Kim et al., 2015).




Figure 1.5 2OG binding within the PHD2 active site. A) Structural view of PHD2 accommodating 2OG. B) 3D illustration showing 2OG chelating the Fe (II) center and interacting with key residues Arg383 and Tyr329 (Chowdhury et al., 2020) (PDB: 3OUJ) (Rosen et al., 2010).

1.6 2OG dependent oxygenases (2OGXs)

The 2-oxoglutarate dependent oxygenases (2OGXs) superfamily comprises around 60-70 enzymes in humans, categorized into nucleotide-modifying enzymes, like the ten-eleven translocation methylcytosine dioxygenase (TET) family for DNA demethylation, and protein-modifying enzymes, such as hydroxylases and demethylases. These enzymes share a common catalytic domain with a distorted double-stranded β -helix (DSBH) fold, providing specificity in substrate recognition. 2OGXs use Fe (II), 2OG, and oxygen as cofactors to catalyze oxidative reactions that produce CO₂ and succinate as byproducts as depicted in Figure 1.2 above. Their targets encompass proteins, nucleic acids, lipids, and small molecules, frequently associated with peptides. The most common reactions are hydroxylation, with occasional demethylation via hydroxylation. These enzymes are involved in essential processes such as gene regulation, DNA repair, and hypoxia sensing. Additionally, they play key roles in secondary metabolism, including β -lactam biosynthesis. The biochemical flexibility and specificity of 2OGXs highlight their significance in primary and secondary metabolism, with important implications for human health and therapeutic applications (Islam et al., 2018a).

Crystallographic studies reveal that 2OGXs are defined by a distorted double-stranded β -helix (DSBH) core fold, also known as a jelly-roll motif (Figure 1.6 A). This right-handed, class I DSBH fold is the only one of four theoretical DSBH topologies observed in nature and is shared by cupin and JmjC domain proteins, many of which are 2OGXs. The DSBH fold in 2OGXs was first predicted from studies on isopenicillin N synthase (IPNS), an enzyme structurally homologous to but mechanistically distinct from 2OGXs. Its presence was later confirmed through crystallographic analyses of enzymes such as deacetoxycephalosporin C synthase

(DAOCS), taurine dioxygenase, and clavaminic acid synthase, which also identified subfamily-specific structural features (Markolovic et al., 2016). A structural representation of the prolyl hydroxylase domain from *Pseudomonas putida* (PPHD), a saprophytic soil bacterium, is also provided for comparison (Figure 1.6 B) (Aik et al., 2015).




Figure 1.6 Overall structure of the 2OG oxygenases. A) General 2-dimensional topology of a 2OG oxygenase. B) Three-dimensional representation of the 2OG oxygenase fold adapted from a crystal structure of AlkB (PDB ID: 3BIE) (Aik et al., 2015).

The functional classification of 2OGXs is summarized in Figure 1.7, dividing them into nucleotide-modifying enzymes, like TET1-3, and those targeting proteins, including histones and non-histone proteins. A key subgroup, the JmjC-only hydroxylases, catalyze protein hydroxylation, distinct from other JmjC enzymes involved in demethylation. Around 45 of these enzymes function as protein hydroxylases or demethylases, while others target different macromolecules. Table 1.1 details key 2OGX enzymes, highlighting their importance in epigenetic regulation, stress responses, and DNA repair (Fletcher et al., 2020).




Figure 1.7 Functional grouping of 2OG oxygenases (2OGXs) by substrate type and function: Collagen hydroxylases (green), nucleotide hydroxylases (blue), translation factor/ribosomal protein hydroxylases (light blue), protein hydroxylases (yellow), and JmjC histone lysine demethylases (gray). Key enzymes like TET1-3, PHD1-3, FIH, and various KDMs highlight their roles in nucleotide, HIF, and histone regulation (Fletcher et al., 2020).

Table 1.1 Some of key 2OGXs, their function and relevant diseases (Fletcher et al., 2020; Yang et al., 2024).

2OGXs/Code	Members	Function	Relevant Diseases
HIF- prolyl hydroxylases (PHDs)	EGLN2 / PHD1, EGLN1 / PHD2, EGLN3 / PHD3	hydroxylation reactions	Cancer, Ischemic disorders, Fibrosis, Erythrocytosis, Metabolic disorders
Jumonji C domain-containing histone lysine demethylases (JmjC-KDMs)	KDM2A-B, KDM3A-C, KDM4A-D, KDM5A-D, KDM6A-C, KDM7A-C	Histone demethylation	Cancer, Neurological disorder
Nucleotide Hydroxylases	ABH1, ABH2, ABH3, ABH4, ABH5, ABH6, ABH7, ABH8, FTO, TET1, TET2, TET3, TYWS	DNA/RNA demethylation	Cancer, Metabolic disease, Neurological disorder
Lysine hydroxylases (LHs)	LH1, LH2, LH3	Collagen post-translational modification	Connective tissue disorder, Fibrosis, Cancer
Collagen Hydroxylases	P4HA1, P4HA2, P4HA3, LEPREL1, LEPREL2, LEPREL3	collagen hydroxylation	Breast cancer, Scurvy, Fibrotic
Translation Factor/Ribosomal Protein Hydroxylases	JMJD4, NO66, MINA, OGFOD1	Translating DNA into proteins	Cancer, Immune dysfunction
Other Protein Hydroxylases	JMJD5, JMJD6, JMJD7, JMJD8, HSPBAP1	//	Neurodegenerative disorder, Inflammation, Cancer.

This research primarily focused on PHDs, particularly PHD2 and PHD3, where our novel series of carbamoyl derivatives (CDs) (**AMS-1 to AMS-19**) demonstrated good activities for both. PHD2 is the most physiologically significant isoenzyme, contributing to the cellular response to hypoxia, and represents a promising therapeutic target for diseases such as cancer (Sameti et al., 2023). To assess selectivity, we also explored other 2OGXs including factor inhibiting HIF (FIH), Jumonji domain-containing protein 6 (JMJD6) and lysine demethylase 4A (KDM4A). FIH regulates HIF by hydroxylating asparagine residues, complementing PHD's role in oxygen sensing. The KDM and JmjC families, including KDM4A and JMJD6, play central roles in epigenetic regulation and gene expression by modifying histones and other proteins, impacting cellular processes such as transcription and RNA splicing. Collectively, these 2OGXs are critical to understanding cellular responses to environmental stresses and are potential targets for therapeutic interventions (Yang et al., 2024).

1.7 PHD diversity and distribution

PHD enzymes are evolutionarily conserved across a wide range of organisms, reflecting their fundamental biological roles. Although considerable research has concentrated on these enzymes in mammals, especially in cells of mammalian, a comparable hydroxylase has been discovered in the plant *Dictyostelium*. In *Dictyostelium*, the PHD enzyme catalyses the hydroxylation of SKP1, a homolog of the FBOX component of the E3 ubiquitin ligase (McDonough et al., 2006; Van der et al., 2005).

Caenorhabditis elegans and *Drosophila* respectively possess a single family member within this category. In *Drosophila*, PHD is known as dHPH (Smith et al.,

2010), while in *C. elegans*, it goes by the name egg laying nine (EGL-9 or EGLN) due to its essential role in egg-laying (Powell et al., 2010). In contrast, mammals exhibit four members within this subfamily, which include PHD1 (EGLN2), PHD2 (EGLN1), PHD3 (EGLN3) and a newly categorized protein referred to as P4HTM (Koivunen et al., 2007; Sears et al., 2011; Trichonas, et al., 2013). Various terms have been used for mammalian homologs, such as HIF-P4H1, HIF-P4H3 and SM-20 for rat PHD3, signifying hydroxylation on the fourth position of proline residues in HIF (Hirsila et al., 2003). It's worth noting that the term 'PHD proteins' aptly describes their functionality as hydroxylases while avoiding exclusive association with HIF substrates, as non-HIF substrates also exist (Fitzpatrick et al., 2016; Fong et al., 2008).

1.7.1 PHD Isoforms

PHD enzymes (PHD1, PHD2, and PHD3) are vital dioxygenases that regulate HIFs, which facilitate cellular adaptation to fluctuating oxygen levels. These enzymes were first identified in 2001 and show a central role in the HIF-mediated hypoxia signaling pathway by hydroxylating HIF- α , marking it for degradation under normoxic conditions. Despite sharing 40%-60% sequence similarity (Figure 1.8), PHD isoforms have evolved distinct physiological roles and tissue-specific expression patterns (Appelhoff et al., 2004). PHD2 is the most ubiquitous isoform, primarily responsible for HIF- α degradation across maximum tissues, while PHD1 is predominantly expressed in the testis, and PHD3 is abundant in the heart (Hoang et al., 2022). These isoforms not only differ in their expression but also in their substrate preferences and physiological functions (Kim et al., 2015; Schödel et al., 2019). For instance, PHD1-deficient mice exhibit enhanced hypoxia tolerance through reprogramming for anaerobic metabolism in skeletal muscle and liver, while PHD2 deficiency results in

embryonic lethality due to critical developmental flaws in the heart and placenta. In contrast, the loss of PHD3 causes a hypofunctional sympathoadrenal system, resulting in lower blood pressure and altered cardiovascular responses. PHD3 is also highly inducible by hypoxia and targets a broader range of substrates, including pyruvate kinase M2 and apelin, highlighting its unique role beyond HIF- α regulation (Demandt et al., 2021).




Figure 1.8 Sequence alignment of human PHD1-3 (Flashman et al., 2008). Asterisks (*) denote highly conserved residues, colons (:) indicate moderately conserved residues, and periods (.) represent the least conserved residues. The alignment was generated using ClustalX 2.1 software.

1.7.2 Structural characteristics of PHDs

The whole human PHD1, PHD2, and PHD3 include 407, 426, and 239 amino acid residues, respectively. They share a highly conserved catalytic domain at the C-terminal, displaying around 55% sequence identity (Figure 1.8). This domain contains a double-stranded β -helix (DSBH) core, typical for 2OGXs, which forms the catalytic center essential for their hydroxylase activity (Tarade et al., 2021). The N-terminal

regions, however, are more variable, with PHD3 featuring the shortest N-terminal domain. Crystallographic studies have revealed detailed insights into PHD2's structure, particularly in its complex with Fe (II) and a 2OG analogue, 2-[(4-hydroxy-8-iodoisoquinolin-3-yl)formamido]acetic acid (4HG) inhibitor as shown in Figure 1.9 (PDB ID: 2G19) . The secondary structure shows the DSBH core stabilized by three α -helices and anti-parallel β -strands. The β 2/ β 3 loop, comprising residues 237-254, plays a critical role in substrate recognition and stabilization, undergoing significant conformational changes upon binding the HIF-1 α CODD peptide. This structural adaptability facilitates substrate specificity and supports the enzyme's catalytic function. Additionally, PHD2's structure is stabilized by its interaction with Fe (II), which is coordinated within the catalytic center, further enhancing its regulatory role in oxygen sensing (Fiorini et al. 2024).

Together, the differences in expression patterns, substrate preferences, and structural features underscore the complexity of the PHD family and their essential roles in regulating HIF-mediated responses to hypoxia. These enzymes serve as key therapeutic targets for a range of diseases, such as cardiovascular conditions, cancer and metabolic disorders, where impaired hypoxia signaling plays a role in disease progression (Shan et al., 2023).

Mn²⁺ and Ni²⁺ are often used as substitutes for Fe²⁺ in proteins like PHD2 because they are less prone to oxidation and can mimic the coordination geometry of Fe²⁺ (Deng et al., 2013; Holt-Martyn et al., 2019). These ions help maintain the protein's active conformation during crystallization (Handing et al., 2018).




Figure 1.9 Stereo view ribbon diagram depicting the secondary structure of the catalytic domain of PHD2, which is bound to the 2-[(4-hydroxy-8-iodoisoquinolin-3-yl)formamido]acetic acid (4HG) (highlighted in green). The active site Fe (II) ion is represented as an orange sphere (PDB ID: 2G19) (McDonough et al., 2006).

1.7.3 PHDs as oxygen sensors

PHDs play a critical role in sensing oxygen levels within cells (Pientka et al., 2012). They act as oxygen sensors by detecting changes in oxygen concentrations and influencing the stability of HIF-1 α (Smith et al., 2015). PHD2, in particular, has garnered attention for its unique characteristics that allow it to function as an efficient oxygen sensor. Researchers have reported that the apparent K_m values for oxygen binding to PHDs are around 240 μ M, which is slightly higher than the physiological concentration of dissolved oxygen in the atmosphere ($\sim$ 200 μ M) (Fandrey et al., 2006). Interestingly, a studies had suggested a higher K_m value of approximately 1.7 mM for oxygen in PHD2 (Yeoh et al., 2012). Additionally, kinetic investigations have revealed that PHD2 exhibits a slower reaction rate when reacting with oxygen, distinguishing it from other 2OGXs (Domene et al., 2020). These features higher K_m values and slower reaction rates contribute to PHD2' sensitivity to changes in oxygen levels

(Kearney, 2015). Significantly, the importance of PHD2 as a primary human oxygen sensor is emphasized by studies utilizing small interfering RNA (siRNA). Targeted reduction of PHD2 mRNA levels, even under normal oxygen conditions, results in the stabilization of HIF-1 α . This underscores the crucial role of PHD2 in regulating HIF-1 α stability in an oxygen-dependent manner (Fang et al., 2005). In contrast, downregulation of PHD1 and PHD3 mRNA levels has minimal impact on HIF-1 α expression across various cell types. This indicates that PHD2 has a more central role in oxygen sensing compared to the other PHD isoforms (Matoba et al., 2013; Pientka et al., 2012).

The findings are further supported by research demonstrating that PHD2 has the greatest specificity for the primary hydroxylation site of HIF-1 α , known as CDD (Yeoh et al., 2012). Moreover, PHD2 is regarded as the ancestral variant of the PHD (EGLN) gene family, as evidenced by research on the nematode *C. elegans* (Ma et al., 2022).

1.8 Problem statement

Hypoxia-related diseases, including anemia, chronic kidney disease (CKD), and cardiovascular diseases (CVDs) are among the leading contributors to global mortality. Cardiovascular illnesses contribute for around 17.9 million deaths per year, constituting 32% of total global mortality (Luo et al., 2024). Anemia, which affects around 15% of the global population (Hess et al., 2023), further compromises oxygen delivery, leading to a 40% rise in cardiovascular complications and a 30% increase in mortality risk, as highlighted by the 2022 WHO statistics (Bianchi et al., 2024). Similarly, CKD represents a growing global health crisis, with renal hypoxia impacting an estimated 850 million people worldwide and approximately 700 million

diagnosed with CKD. The global rate of chronic kidney disease (CKD) increased by 33% from 1990 to 2017, with the most significant rise observed in countries with low or middle incomes, notably China and India (Francis et al., 2024).

To address these pressing issues, a promising therapeutic strategy lies in activating hypoxia inducible factors (HIF) by inhibiting prolyl hydroxylase domain (PHD) enzymes. This method stabilizes HIF and triggers protective pathways under hypoxic conditions. However, existing PHD inhibitors present significant limitations, including toxicity, thromboembolic risks, and high costs, underscoring the urgent need for safer and more effective alternatives (Locatelli et al., 2022).

This study aims to address the limitations of current PHD-targeted therapies by using computer-aided drug design (CADD) to develop novel inhibitors. Objectives include elucidating the molecular basis of PHD inhibition, designing compounds based on structure-activity relationships (SAR), and evaluating their therapeutic potential. To achieve this, natural, synthetic, and purchasable compounds including those from the REAL database of EnamineStore will be screened. The findings are expected to advance the understanding of hypoxia-related diseases and aid in the development of innovative treatments. *In silico* methods such as virtual screening (VS), induced fit docking (IFD), and molecular dynamics simulations (including RMSD, Rg, RMSF, hydrogen bond analysis, MM/GBSA calculations, and SASA) are employed to predict the binding affinities and inhibitory potential of top-performing compounds (Sayaf et al., 2024). Additionally, AutoQSAR modeling is used to enhance the predictive accuracy of compound efficacy.

In addition, a novel series of carbamoyl derivatives (CDs) was evaluated using IFD. These compounds were selected based on previous findings that 3-

carbamoylpropanoic acid (3CA) derivatives derived from succinic anhydride exhibit potent *in vitro* PHD2 inhibition (e.g., F2a, $IC_{50} = 2.24 \mu M$; F2b, $IC_{50} = 1.32 \mu M$) (Chong et al., 2021), highlighting their potential as promising scaffolds for further PHD2 inhibitor development. The incorporation of maleic and glutaric anhydrides in the present study was intended to broaden structural diversity and explore structure–activity relationships (SAR) with the goal of enhancing both inhibitory potency and pharmacokinetic properties.

1.9 Research objectives

To address the above concerns and optimize the discovery of novel PHD inhibitors, the following aims are covered in this thesis:

1. To explore natural and synthetic compounds from diverse databases, including AnalytiCon Discovery Natural Product (NP), AfroDb Natural Products, Herbal Ingredients Targets, HIM-Herbal Ingredients *in vivo* Metabolism, IBScreen NP, Indofine NP, and Naturally Occurring Plant based Anticancer Compound-Activity-Target Database (NPACT) as well as regional African databases (East, North, North-East, and South Africa) and the Comprehensive Marine Natural Products Database (CMNPD), for the discovery of promising PHD inhibitors using *in silico* approaches including molecular docking and molecular dynamics simulations.
2. To investigate the inhibitory potential of REAL database compounds from EnamineStore against PHDs through integrated *in silico* and *in vitro* assays.
3. To design, synthesize, and evaluate a novel series of carbamoyl derivatives (CDs) as potential PHD inhibitors through integrated *in silico* modeling and *in vitro* biological analysis.

1.10 Scope of study

To identify potential PHD2 inhibitors, a comprehensive dataset comprising 147,583 compounds in 3D-SDF format was compiled from a wide range of publicly available and commercially accessible sources. These included the East African Natural Products Database (EANPDB), North African Natural Products Database (NANPDB), North East African Natural Products Database (NEANPDB), South African Natural Products Database (SANCDB), Comprehensive Marine Natural Products Database (CMNPD), Naturally Occurring Plant-based Anti-cancer Compound-Activity-Target (NPACT), Indofine Natural Products, InterBioScreen (IBScreen), AfroDb, AnalytiCon Discovery Natural Products (NP), Herbal Ingredients Targets, and Herbal Ingredients in vivo Metabolism (HIM). In addition, purchasable small-molecule analogues from the REAL database of EnamineStore were included to enhance the translational potential of identified hits. The selection of compounds from these databases was guided by multiple criteria, including natural product origin, structural diversity, reported or predicted bioactivity, physicochemical properties compliant with Lipinski's Rule of Five (RO5), and potential relevance to hypoxia-related targets such as prolyl hydroxylase domain (PHD) enzymes. This curated and diverse compound library served as the foundation for subsequent virtual screening and molecular modeling studies.

To ensure drug-likeness, we applied Lipinski's Rule of Five (RO5) using the FAF Drugs4 web server. Compounds that passed the rule were prepared and subjected to screening against the PHD2 active site using ligand-based and structure-based techniques. The compounds explored interact with key residues such as Arg383, Tyr329, Tyr303, and Asp254, while also forming bidentate coordination with the iron (II) ion in the PHD2 active site.

In silico drug design techniques, including binding free energy estimation and binding pose analysis based on crystallographic data from the PDB, were employed. Molecular dynamics simulations, including RMSD, Rg, RMSF, hydrogen bond analysis, MM/GBSA calculations, and SASA, were conducted by Dr. Abbas Khan at Qatar University and Shanghai Jiao Tong University.

The synthesized CDs were analyzed using multiple spectroscopic techniques, such as Fourier-transform infrared spectroscopy (FT-IR) and Nuclear magnetic resonance (NMR) (1D and 2D), at the School of Chemical Sciences, Universiti Sains Malaysia.

Part of this research (Chapter 7) was conducted under the supervision of Professor Dr. Christopher J. Schofield from the Schofield Group (CJS), Chemistry Research Laboratories (CRL), University of Oxford. High-resolution mass spectrometry (HRMS) of the CDs was analysed with Thomas Corner, and the expression of PHD3 protein was investigated with Dr. Eidarus Salah and Parsa Jabbary. Furthermore, compounds purchased from the REAL database of EnamineStore and successfully synthesized CDs were tested for inhibitory potency against PHD2, PHD3, and FIH, using the Solid phase extraction mass spectrometry (SPE-MS), conducted together with Dr. Anthony Tumber and Dr. James Holt-Martyn, while CPMG NMR binding studies for **AMS-12** from synthesized CDs were performed with Sam Atwal from CJS at CRL, University of Oxford.

This comprehensive approach aims to identify potent and selective PHDs inhibitors with therapeutic potential for treating hypoxia-related diseases.

CHAPTER 2

LITERATURE REVIEW

This review begins with a historical overview of HIF and PHD enzymes, tracing their discovery and evolution, and then delves into the genes associated with HIF. It explores the therapeutic benefits of activating HIF through PHD inhibition, highlighting its potential to impact disease treatment and management. The role of PHDs in drug discovery is also examined, emphasizing their potential as promising targets for novel therapeutics. A significant portion of the review focuses on reported PHD inhibitors, categorized by their chemical structure and mechanisms of action. This includes a detailed analysis of 2-oxoglutarate (2OG) analog inhibitors, such as: (i) carboxylic acid-based PHD inhibitors (CABPIs) like N-oxalylglycine (NOG) and its derivatives (quinoline, pyridine, benzimidazole), and (ii) non-carboxylic acid-based inhibitors (NCABPIs), including quinazolines, hydroxypyridones, and spiroindolones, along with non-conventional PHD inhibitors (NCPIs) like phenolic derivatives and pyrrithione zinc complexes.

The review also discusses the importance of amide bond formation in PHD2 inhibitor design, highlighting the role of amides in drug design and recent advances in their synthesis. Finally, the applications and limitations of CADD are explored, emphasizing its crucial role in discovering and developing PHD inhibitors. This literature review offers an extensive overview of the existing research on PHD enzymes and their inhibitors, establishing a foundation for future investigation and advancement in this evolving field of biomedical science.

2.1 Historical overview of HIF research

The exploration of HIFs has profoundly enhanced our understanding of cellular responses to low-oxygen conditions. The chronological evolution of HIF research, highlighting key milestones is summarized in Table 2.1. This scientific journey began in 1991 with the groundbreaking identification of HIF-1 as a member of the basic helix-loop-helix-PER-ARNT-SIM (bHLH-PAS) superfamily. This discovery, led by Semenza GL and colleagues, established the pivotal role of HIF-1 in regulating genes associated with angiogenesis, erythropoiesis, and glucose metabolism (Semenza, et al., 1991). Subsequent progress in 1995 by Wang GL and collaborators elucidated the dimerization and transactivation properties of HIF-1, providing key insights into the molecular mechanisms of HIF-mediated gene expression (Wang et al., 1995). In 1999, focus turned to the VHL tumour suppressor protein, which was demonstrated to facilitate the proteasomal degradation of hydroxylated HIF-1 α in normoxic circumstances. This critical finding by Maxwell PH and his team underscored the significance of HIF-1 α regulation in maintaining cellular oxygen homeostasis (Maxwell et al., 1999). The same year, the overexpression of HIF-1 α in various human cancers further highlighted the role of HIF dysregulation in tumorigenesis (Maxwell et al., 1999). Early 2000s marked a major breakthrough with the identification of PHD enzymes as key regulators of HIF stability. In 2001, researchers identified that PHD enzymes hydroxylate particular proline residues in HIF- α subunits, resulting in their breakdown and modulating HIF activity (Ivan et al., 2001). Further advancements in 2002 demonstrated that HIF-1 α transcriptional activity could be negatively regulated, shedding light on the intricate control mechanisms governing HIF-mediated gene expression (Wang et al., 1995). In 2003, studies expanded the understanding of cell-specific hypoxic responses, revealing that different cell types exhibit distinct HIF